Objective. To verify the relationship between vaginal pH and human papillomavirus (HPV) infection and to measure cytokine levels in endocervical secretions of women with bacterial vaginosis (BV) or HPV. Methods. 173 women (16-48 years old) were enrolled and divided into groups: BV, HPV, and controls. Microbiological culture and vaginal pH were measured. HPV detect by PCR, and cytokines by ELISA...

OBJECTIVE The aim of the study was to evaluate the safety and efficacy of vaginal estradiol (E2) softgel capsules for moderate-to-severe symptoms of vulvar and vaginal atrophy (VVA). Previous phase 1 studies showed lower systemic estrogen concentrations with this softgel capsule compared with an approved low-dose vaginal E2 tablet. METHODS In this randomized, double-blind, placebo-controlled ...

BACKGROUND Vulvovaginal atrophy (VVA) is characterized by vaginal/vulvar dryness, irritation, dyspareunia, or dysuria. The objective of this study was to examine the efficacy and safety of a very low-dose estradiol vaginal cream (0.003%) applied twice per week in postmenopausal women with VVA-related vaginal dryness. MATERIALS AND METHODS In this phase 3, randomized, double-blind, placebo-con...

Bacterial vaginosis (BV) is a disorder of the vaginal ecosystem characterized by a shift in the vaginal flora from the normally predominant Lactobacillus to one dominated by sialidase enzyme-producing mixed flora. It is the most common cause of abnormal vaginal discharge in adult women. The BVBlue system (Gryphus Diagnostics, L.L.C.) is a chromogenic diagnostic test based on the presence of ele...

BACKGROUND The 12-week, randomized, double-blind, placebo-controlled, multicenter, phase 3 REJOICE trial demonstrated that TX-004HR, an investigational, applicator-free, low-dose vaginal softgel capsule containing solubilized 17β-estradiol, effectively and rapidly treats symptoms of vulvar and vaginal atrophy (VVA) with negligible to very low systemic absorption. The aim of this analysis was to...

OBJECTIVES This study was designed to evaluate the efficacy of Replens, a non-hormonal moisturizing vaginal gel, on symptoms of vaginal atrophy in postmenopausal women, in comparison with Dienoestrol (Cilag), an oestrogenic vaginal cream. METHODS Thirty-nine patients were randomly allocated to either of the two treatments. Replens was given three times a week during the 12 weeks of the study,...

Introduction Vaginal atrophy (VA) is an irreversible involution of the mucous membranes and tissues of the vagina following the drop in estrogen that commonly occurs in women during menopause (1). Due to a lengthening of the average lifespan and longer life expectancy after menopause, vaginal atrophy is destined to become a clinical problem with an increasingly greater epidemiological significa...

Introduction: This study was conducted to evaluate the efficacy of 800µg vaginal misoprostol after wetting alkaline PH vagina with 3% acetic acid in comparison with 800µg vaginal misoprostol alone in the alkaline PH vagina in terminating first trimester pregnancies. Methods: In this clinical trial, a total of 100 healthy women between 20 and 40 years old requesting legal terminat...

background: vaginal atrophy is a common complication in menopause which does not improve with time and, if untreated, can affect the quality of life for women. the aim of this study was to compare the effectiveness of the vaginal cream of hyaluronic acid and conjugated estrogen (premarin) in treatment of vaginal atrophy. methods: this study was a randomized controlled clinical trial on 56 menop...